AXON Neuroscience, a Clinical-stage Biotech Company to Launch World's First Crowdfunded Vaccine Against Covid-19

COVIDAX | September 19, 2020

AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1. With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine against COVID-19. Axon's scientists identified the weakest points of the SARS-CoV-2 virus and used them to design the vaccine. ACvac1 induced extensive antibody production in vaccinated mice, effectively blocking the live virus from replicating and confirming the soundness of Axon's approach. Axon plans to begin first-in-human trials as early as the fourth quarter of 2020. Based on these encouraging vaccine efficacy results, Axon has decided to open the project to individuals and small investors who will be able to invest directly from the project's website.

Spotlight

This technical note demonstrates the comprehensive
characterization and confident identification of glucuronide
metabolites from hepatocyte incubations of midazolam. An
orthogonal fragmentation mechanism was applied to generate diagnostic fragment ions for confident identification of glucuronide metabolites

Spotlight

This technical note demonstrates the comprehensive
characterization and confident identification of glucuronide
metabolites from hepatocyte incubations of midazolam. An
orthogonal fragmentation mechanism was applied to generate diagnostic fragment ions for confident identification of glucuronide metabolites

Related News

INDUSTRIAL IMPACT, MEDICAL

Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology

Businesswire | April 24, 2023

Guardant Health, Inc. a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023. “Despite multiple screening modalities for colorectal cancer, screening rates remain stubbornly low leaving many cancers undetected. A blood test that can accurately detect CRC represents a significant opportunity to overcome some of the known challenges with patient adherence,” said AmirAli Talasaz, Guardant Health co-CEO. “We are thrilled that DDW has accepted the ECLIPSE study, one of the largest studies of its kind, as a late-breaking abstract, and we look forward to sharing this new data with the healthcare community at this year’s meeting.” “The need for a convenient, less invasive way to screen for CRC is great, and an accurate blood test can play a critical role in improving screening rates, especially for those reluctant to get screened,” said Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. “I look forward to presenting at DDW and sharing new data from the ECLIPSE Study on the performance and potential of the Shield blood test to help improve adherence to screening." About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.

Read More

INDUSTRIAL IMPACT, MEDICAL

Asahi Kasei Bioprocess America and GeminiBio Enter Strategic Partnership to Advance Application of Inline Buffer Formulation

businesswire | April 20, 2023

Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation (IBF) in the biopharmaceutical industry. Asahi Kasei Bioprocess, with decades of expertise in IBF and the developers of the award-winning MOTIV™ system, and GeminiBio, with industry leading bioprocess liquid manufacturing capabilities, are combining two high-efficiency solutions for buffer management to biopharmaceutical manufacturers in one package. This will result in fewer bottlenecks in manufacturing, streamlining the IBF process. The companies entered the agreement in March 2023 with the initial scope of the North American biopharmaceutical industry. Buffers are used extensively in the development and manufacturing process for all biopharmaceuticals. The manufacturing of buffers is time consuming and resource intensive, and often a significant bottleneck in the biopharmaceutical manufacturing process. The Asahi Kasei Bioprocess MOTIV IBF™ system is built specifically to debottleneck downstream processing to move product more efficiently through the manufacturing process. However, creating the buffer concentrates that are used with these systems has remained a challenge. Pairing MOTIV with GeminiBio’s pre-mixed concentrates provides biopharmaceutical manufacturers a total solution, resulting in a new level of efficiency and cost savings throughout the biopharmaceutical manufacturing process, yielding benefits throughout the entire value chain. “Our partnership with GeminiBio solidifies both companies’ commitment to improving the efficiency and efficacy of buffer formulation,” says Chris Rombach, Senior Vice President of Sales and Marketing at Asahi Kasei Bioprocess America. “The combination of Asahi Kasei Bioprocess America’s long-standing buffer formulation expertise and GeminiBio’s state-of-the-art buffer concentrate manufacturing capabilities will aid bioprocessors to reduce costs, minimize facility footprint and assure on time, every time buffer production.” Moving forward, while this collaboration will provide biopharmaceutical manufacturers with immediate benefit, the value is expected to increase exponentially over time with the open sharing of data and joint testing that will spur innovation at both companies. The MOTIV system will be better acclimated to immediately support a wider variety of pre-mixed buffer concentrates as the variety of the concentrates diversifies. ”We are excited to collaborate with Asahi Kasei Bioprocess to help the biotech industry further address the buffer bottleneck”, said Brian Parker, CEO of GeminiBio. “GeminiBio is committed to helping our customers simplify upstream and downstream process liquid manufacturing, and supporting inline dilution with ready to use buffer concentrates for the MOTIV IBF™ system allows us to provide an even higher level of simplification for our customers.” The partnership between Asahi Kasei Bioprocess America and GeminiBio exemplifies the dedication of the Asahi Kasei Group to its mission of contributing to life and living for people around the world as it paves the way to innovation under their current medium-term management plan: Be a Trailblazer. About Asahi Kasei Bioprocess The Fluid Management Business Unit of Asahi Kasei Bioprocess is devoted to solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for oligonucleotide synthesis, buffer formulation, chromatography, and filtration, our bioprocess systems, columns, and automation solutions advance GMP manufacturing of critical drug substances around the world. Built with pride, built with quality, built to exceed expectations.

Read More

MEDTECH, MEDICAL

Twist Bioscience Launches Portfolio of RNA Sequencing Tools

Businesswire | May 23, 2023

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a portfolio of RNA sequencing tools, which includes the Twist RNA Exome, Twist RNA Library Prep Kit and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing. This comprehensive suite of RNA tools can enable targeted or whole transcriptome research across fields including precision medicine, biomarker discovery and immuno-oncology research. “Twist’s RNA sequencing portfolio builds on our established NGS capabilities in genomic sequencing and methylation detection and expands into gene expression analysis, opening a new and significant market for Twist,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “This offering allows our customers to leverage Twist’s leading target enrichment platform to discover and resolve low abundance RNA transcripts in the human transcriptome. Our RNA sequencing workflows are designed specifically for challenging samples. By enriching relevant transcripts, we can enable researchers to get high-quality data from a range of sample types, including damaged RNA.” Unlike the genome, which is relatively static, the transcriptome changes over time in response to varying disease states and drug therapies. Gene expression levels also differ across tissues and cell types. To fully understand this dynamic quality of RNA, researchers often sequence RNA samples from the same source at multiple time points, incurring additional costs and resource burdens. Each component of the Twist RNA sequencing portfolio is purpose-built to maximize data quality, minimize workflow inefficiency, decrease wasted sequencing reads, and support comprehensive transcriptomic profiling across even low-quality and low-input samples common in oncology. The Twist RNA sequencing portfolio provides end-to-end workflows that can be used to study total RNA and measure the whole transcriptome, protein coding sequences of messenger RNA (mRNA) or custom targets. These products can also be integrated into customers’ existing workflows. Twist RNA sequencing tools enable minimal hands-on time and increase the scale of samples sequenced through utilizing automation. They are compatible with a wide range of sample inputs, including difficult or low-quality samples. RNA panel designs can also now incorporate Twist’s new exon-aware design algorithm, which reduces bias in detection and can provide an important tool for researchers studying rare gene transcripts that drive tumor biology. Twist Targeted RNA Sequencing Workflow Twist target enrichment for RNA leverages the performance, efficiency and sensitivity of Twist target enrichment for sequencing of RNA transcripts of interest across samples and species. It can be used to enrich relevant transcripts with the RNA Exome or in custom RNA panels. Twist RNA Exome The Twist RNA Exome with Twist’s exon-aware design algorithm enables targeted sequencing of the protein coding regions of the human transcriptome without bias toward specific combinations of exons. The Twist RNA Exome covers up to 99.9% of protein coding sequencing in Gencode and RefSeq databases. This coverage, along with the exon-aware design approach, could enable researchers to capture important transcripts including those in low input and degraded samples from formalin fixed paraffin embedded (FFPE) sections. Twist Whole Transcriptome Sequencing Workflow Twist Whole Transcriptome Sequencing can be used to discover novel transcripts, including low expressing genes and novel isoforms. It can be used with a variety of samples including whole blood, fresh and frozen tissue samples and low quality samples, such as FFPE samples. The Twist rRNA & Globin Depletion Kit can be used with this workflow to deplete rRNA and hemoglobin targets so that researchers can study the rest of the transcriptome. The full workflow can be completed in less than five hours with minimal hands-on time. About Twist Bioscience Corporation Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Read More